Breast Invasive Lobular Carcinoma
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma of the breast arising from the lobules. This is a relatively uncommon carcinoma, represents approximately 10% of the breast adenocarcinomas and is often bilateral or multifocal. 
Breast invasive lobular carcinomas most frequently harbor alterations in CDH1, PIK3CA, TP53, ERBB2, and CCND1 .
CDH1 Mutation, PIK3CA Mutation, PIK3CA H1047R, TP53 Mutation, and CCND1 Amplification are the most common alterations in breast invasive lobular carcinoma .
There are 2 clinical trials for breast invasive lobular carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain breast invasive lobular carcinoma as an inclusion criterion, 1 is early phase 1 (1 open) and 1 is no phase specified (1 open).
ERBB2 is the most frequent gene inclusion criterion for breast invasive lobular carcinoma clinical trials .
Imipramine, anastrozole, and fulvestrant are the most common interventions in breast invasive lobular carcinoma clinical trials.
Significant Genes in Breast Invasive Lobular Carcinoma
ERBB2 is altered in 11.0% of breast invasive lobular carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for breast invasive lobular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and breast invasive lobular carcinoma as inclusion criteria, 1 is early phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.